PM360

OCTOBER 13, 2023

Doctor Docs: Targeting Trust Between Pharma and HCPs A new study shows the crucial link in pharma marketers’ digital engagement strategy with HCPs is in jeopardy—trust. doctors are calling two particular drugs “paradigm-shifting”—tirzepatide, sold as Mounjaro , and semaglutide, sold as the brands Ozempic , Wegovy , and Rybelsus.

Healthcare 59

Healthcare Healthcare Doctors Pharma 59

pharmaphorum

DECEMBER 22, 2022

Prediction 1: the FDA will become more directive and collaborative on guidelines for DCTs. The risk of not having these discussions is to conduct expensive trials only to discover too late that they were measuring the wrong endpoint, in the wrong way, or with a tool or technology the FDA does not accept.

FDA 85

FDA Patients Electronics Medical 85

pharmaphorum

SEPTEMBER 30, 2022

Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that arrived at different conclusions about the drug. The drug was also filed for approval in Europe in February, with a decision due in early 2023.

FDA 87

FDA Doctors Patients Prescription 87

European Pharmaceutical Review

APRIL 13, 2023

The Schedule 1 classification means that these substances cannot be administered by doctors and, though they may be used for the purposes of research a government licence is often required. The US Food and Drug Administration (FDA) has decided to fast-track psilocybin for depression, with full support from President Biden’s administration.

Medicine 114

Medicine Food and Drug Administration Doctors Government 114

PM360

AUGUST 9, 2022

Doctors, caregivers, life sciences companies, and even companies in other industries have attempted to answer this question for as long as medications have been available. Unlike other formulary optimization solutions, Levrx delivers plan-specific and real-time prescription insights. But it is not a simple answer. Vincent Keunen.

Prescription 105

Prescription Medical Side effects Patients 105

pharmaphorum

JANUARY 9, 2023

This Nine for 2023 three-part series will argue that, this year, the future-facing Janus prediction of unprecedented and transformative change is true. However, the pandemic is only one of the often deep-rooted forces that will come together in 2023 to exert transformative pressure on healthcare.

Medicine 89

Medicine Healthcare Healthcare Pharma 89

pharmaphorum

JANUARY 25, 2023

Digital therapeutics company Woebot Health has announced enrolment of the first patient in a pivotal clinical trial to evaluate the safety and efficacy of WB001, an investigational therapeutic for postpartum depression (PPD), granted Breakthrough Device designation by the US Food and Drug Administration (FDA) in 2021. Levy asked.

Food and Drug Administration 92

Food and Drug Administration Prescription Media FDA 92